Category Archives: Intravenous immuneglobulin

Update: Intravenous immunoglobulin in children: part 3

The increased use of IgIV has heightened our recognition of the range of associated adverse events, several of which have been reported since the original committee recommendations. The incidence of aseptic meningitis following IgIV infusion may be higher than previously thought, part icularly with infusion at very high doses (2 g/kg). Non-A, non-B hepatitis had not previously been reported in products licensed in North America; … Continue reading

Update: Intravenous immunoglobulin in children: part 2

Use of IglV prophylactically to prevent intections in low birth weight neonates remains cont roversial. The results of four placebo cont rolled, double-blind studies have recently been reported. One study demonstrated a decreased risk of nosocomial intection in premature intants with birth weights between 500 and 1750 g, alt hough morbidity and mortality were not affected. Two other smaller studies failed to show a beneficial … Continue reading

Update: Intravenous immunoglobulin in children: part 1

The Infectious Diseases and Immunization Committee of the Canadian Paediatric Society made recommendations on the use of intravenous immune globulin (IglV) in children in 1992. Certain conditions were listed in which the efficacy of IglV has been established including replacement therapy in antibody deficiency states, immune thrombocytopenic purpura and Kawasaki disease. Other conditions were listed in which the efticacy of IglV was not yet established. … Continue reading